Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01670877 · ClinicalTrials.gov registry record · Phase 2
Neratinib +/- Fulvestrant in Metastatic HER2 Non-amplified But HER2 Mutant Breast Cancer
A Phase 2 study, sponsored by Washington University School of Medicine.
- Completed
- Registry status
- Phase 2
- Development phase
- 56
- Enrollment target
NCT01670877 is a Phase 2 study that has completed, run by Washington University School of Medicine. The registered enrollment target is 56 participants.
The verdict
NCT01670877, a Phase 2 study, has completed, sponsored by Washington University School of Medicine.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 56 participants
- Enrollment target
Study Summary
This phase II study will test cancer to see if it has a HER2 mutation and, if so, see how HER2 mutated cancer responds to treatment with neratinib.
Interventions
- DRUG Trastuzumab
- DRUG Neratinib
- DRUG Fulvestrant
- PROCEDURE Tumor biopsy
- PROCEDURE Research blood sample
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 56 participants |
| Start Date | 2012-12-11 |
| Est. Completion | 2021-03-11 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01670877
The ClinicalTrials.gov registry entry for NCT01670877 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 56 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Washington University School of Medicine, which has 1,502 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Trastuzumab is the first listed.
NCT01670877 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01670877 about?
NCT01670877 is a clinical study titled "Neratinib +/- Fulvestrant in Metastatic HER2 Non-amplified But HER2 Mutant Breast Cancer". This phase II study will test cancer to see if it has a HER2 mutation and, if so, see how HER2 mutated cancer responds to treatment with neratinib.
What is the current status of trial NCT01670877?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 56 participants. The study started on 2012-12-11. Estimated completion is 2021-03-11.
What interventions are being tested in trial NCT01670877?
The interventions under investigation include: Trastuzumab (DRUG), Neratinib (DRUG), Fulvestrant (DRUG), Tumor biopsy (PROCEDURE), Research blood sample (PROCEDURE).
Who is sponsoring clinical trial NCT01670877?
This trial is sponsored by Washington University School of Medicine, which has 1,502 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.